

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM562314

SUBMISSION TYPE:	RESUBMISSION
NATURE OF CONVEYANCE:	SECURITY INTEREST
RESUBMIT DOCUMENT ID:	900524938

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
PAVmed Inc.		11/04/2019	Corporation: DELAWARE
LUCID DIAGNOSTICS, INC		11/04/2019	Corporation: DELAWARE

RECEIVING PARTY DATA

Name:	ALTO OPPORTUNITY MASTER FUND, SPC - SEGREGATED MASTER PORTFOLIO B
Street Address:	222 Broadway
Internal Address:	C/O AYRTON CAPITAL LLC, 19TH FLOOR
City:	New York
State/Country:	NEW YORK
Postal Code:	10038
Entity Type:	Corporation: DELAWARE

PROPERTY NUMBERS Total: 15

Property Type	Number	Word Mark
Serial Number:	88274813	ESOCHECK CCD
Serial Number:	88347269	ESOGUARD
Serial Number:	88090111	ESOCHECK
Serial Number:	88489556	ESOSURE
Serial Number:	88489562	ESOSURE
Serial Number:	88489566	COLLECT+PROTECT
Serial Number:	88489564	COLLECT+PROTECT
Serial Number:	88202914	PAVMED
Serial Number:	88202918	PAVILION
Serial Number:	88202925	PAVILION MEDICAL
Serial Number:	88202913	PAVMED
Serial Number:	88202911	PPPP
Serial Number:	88202927	INNOVATING AT THE SPEED OF LIFE
Serial Number:	87828085	CARPX
Serial Number:	88602470	DEFY GRAVITY

CORRESPONDENCE DATA**Fax Number:** 2128087897*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.***Phone:** 212-808-7800**Email:** trademarks@kelleydrye.com**Correspondent Name:** RAXAK MAHAT**Address Line 1:** 101 Park Avenue**Address Line 4:** New York, NEW YORK 10178**ATTORNEY DOCKET NUMBER:** 025698-0003**NAME OF SUBMITTER:** Patricia L. Werner, Esq.**SIGNATURE:** /patricialwerner/**DATE SIGNED:** 02/14/2020**Total Attachments: 15**

source=PavMed IP Security#page1.tif

source=PavMed IP Security#page2.tif

source=PavMed IP Security#page3.tif

source=PavMed IP Security#page4.tif

source=PavMed IP Security#page5.tif

source=PavMed IP Security#page6.tif

source=PavMed IP Security#page7.tif

source=PavMed IP Security#page8.tif

source=PavMed IP Security#page9.tif

source=PavMed IP Security#page10.tif

source=PavMed IP Security#page11.tif

source=PavMed IP Security#page12.tif

source=PavMed IP Security#page13.tif

source=PavMed IP Security#page14.tif

source=PavMed IP Security#page15.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This INTELLECTUAL PROPERTY SECURITY AGREEMENT (as amended, modified, supplemented, renewed, restated or replaced from time to time, this “**IP Security Agreement**”), dated November 4, 2019, is made by the Persons listed on the signature pages hereof (collectively, the “**Grantors**”) in favor of Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B, in its capacity as collateral agent (the “**Collateral Agent**”) for the Noteholders. All capitalized terms not otherwise defined herein shall have the meanings respectively ascribed thereto in the Security Agreement (as defined below).

WHEREAS, PAVmed Inc., a Delaware corporation with offices located at One Grand Central Place, Suite 4600, New York, NY 10165 (the “**Company**”), and each party listed as a “Buyer” therein (collectively, the “**Buyers**”) are parties to that certain (i) Securities Purchase Agreement, dated December 27, 2018, pursuant to which the “Buyer” specified therein purchased the “Notes” (as defined therein) issued pursuant thereto (as such Notes may be amended, modified, supplemented, renewed, restated or replaced from time to time in accordance with the terms thereof, collectively, the “**2018 Notes**”), and (ii) the Securities Purchase Agreement, dated as of November 3, 2019 (as amended, modified, supplemented, extended, renewed, restated or replaced from time to time, the “**2019 Securities Purchase Agreement**” and together with the 2018 Securities Purchase Agreement, the “**Securities Purchase Agreements**”) pursuant to which the Company shall be required to sell, and the “Buyers” specified therein shall purchase or have the right to purchase, the “Notes” (as defined therein) issued pursuant thereto (as such Notes may be amended, modified, supplemented, renewed, restated or replaced from time to time in accordance with the terms thereof, collectively, the “**2019 Notes**”, and together with the 2018 Notes, the “**Notes**”);

WHEREAS, it is a condition precedent to the purchase of the Notes under the Securities Purchase Agreements that each Grantor has executed and delivered a Security and Pledge Agreement, made by the Grantors to the Collateral Agent (as amended, modified, supplemented, renewed, restated or replaced from time to time, the “**Security Agreement**”); and

WHEREAS, under the terms of the Security Agreement, the Grantors have granted to the Collateral Agent, for the ratable benefit of the Collateral Agent and the Noteholders, a security interest in, among other property, certain intellectual property of the Grantors, and have agreed as a condition thereof to execute this IP Security Agreement for recording with the U.S. Patent and Trademark Office, the United States Copyright Office and other governmental authorities.

WHEREAS, the Grantors have determined that the execution, delivery and performance of this IP Security Agreement directly benefits, and is in the best interest of, the Grantors.

NOW, THEREFORE, in consideration of the premises and the agreements herein and in order to induce the Buyers to perform under the Securities Purchase Agreement, each Grantor agrees with the Collateral Agent, for the benefit of the Noteholders, as follows

SECTION 1. Grant of Security. Each Grantor hereby grants to the Collateral Agent for the ratable benefit of the Collateral Agent and the Noteholders a security interest in all of such Grantor's right, title and interest in and to the following (the "**Collateral**"):

- (i) the Patents and Patent applications set forth in Schedule A hereto;
- (ii) the Trademark and service mark registrations and applications set forth in Schedule B hereto (provided that no security interest shall be granted in United States intent-to-use trademark applications to the extent that, and solely during the period in which, the grant of a security interest therein would impair the validity or enforceability of such intent-to-use trademark applications under applicable federal law), together with the goodwill symbolized thereby;
- (iii) all Copyrights, whether registered or unregistered, now owned or hereafter acquired by such Grantor, including, without limitation, the copyright registrations and applications and exclusive copyright licenses set forth in Schedule C hereto;
- (iv) all reissues, divisions, continuations, continuations-in-part, extensions, renewals and reexaminations of any of the foregoing, all rights in the foregoing provided by international treaties or conventions, all rights corresponding thereto throughout the world and all other rights of any kind whatsoever of such Grantor accruing thereunder or pertaining thereto;
- (v) any and all claims for damages and injunctive relief for past, present and future infringement, dilution, misappropriation, violation, misuse or breach with respect to any of the foregoing, with the right, but not the obligation, to sue for and collect, or otherwise recover, such damages; and
- (vi) any and all proceeds of, collateral for, income, royalties and other payments now or hereafter due and payable with respect to, and supporting obligations relating to, any and all of the Collateral of or arising from any of the foregoing.

SECTION 2. Security for Obligations. The grant of a security interest in, the Collateral by each Grantor under this IP Security Agreement secures the payment of all Obligations of such Grantor now or hereafter existing under or in respect of the Notes and the Transaction Documents, whether direct or indirect, absolute or contingent, and whether for principal, reimbursement obligations, interest, premiums, penalties, fees, indemnifications, contract causes of action, costs, expenses or otherwise.

SECTION 3. Recordation. Each Grantor authorizes and requests that the Register of Copyrights, the Commissioner for Patents and the Commissioner for Trademarks and any other applicable government officer record this IP Security Agreement.

SECTION 4. Execution in Counterparts. This IP Security Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement.

SECTION 5. Grants, Rights and Remedies. This IP Security Agreement has been entered into in conjunction with the provisions of the Security Agreement. Each Grantor does hereby acknowledge and confirm that the grant of the security interest hereunder to, and the rights and remedies of, the Collateral Agent with respect to the Collateral are more fully set forth in the Security Agreement, the terms and provisions of which are incorporated herein by reference as if fully set forth herein.

SECTION 6. Governing Law; Jurisdiction; Jury Trial.

(i) All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of New York.

(ii) Each Party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in The City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith or under any of the other Transaction Documents or with any transaction contemplated hereby or thereby, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim, defense or objection that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof to such party at the address for such notices to it under Section 9(f) of each of the Securities Purchase Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law. Nothing contained herein shall be deemed or operate to preclude the Collateral Agent or the Noteholders from bringing suit or taking other legal action against any Grantor in any other jurisdiction to collect on a Grantor's obligations or to enforce a judgment or other court ruling in favor of the Collateral Agent or a Noteholder.


(iii) WAIVER OF JURY TRIAL, ETC. EACH PARTY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR UNDER ANY OTHER TRANSACTION DOCUMENT OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT, ANY OTHER TRANSACTION DOCUMENT OR ANY TRANSACTION CONTEMPLATED HEREBY OR THEREBY.

(iv) Each Party irrevocably and unconditionally waives any right it may have to claim or recover in any legal action, suit or proceeding referred to in this Section any special, exemplary, indirect, incidental, punitive or consequential damages.


[The remainder of the page is intentionally left blank]

IN WITNESS WHEREOF, each Grantor has caused this Agreement to be duly executed and delivered by its officer thereunto duly authorized as of the date first above written.

PAVMED INC.

By 
Name: Lishan Aklog
Title: Chief Executive Officer

LUCID DIAGNOSTICS, INC.

By 
Name: Lishan Aklog
Title: Executive Chairman

Address for Notices:

One Grand Central Place
Suite 4600
New York, New York 10165

Schedule A (Patents) and Schedule B (Trademarks)

PAVMED (155848) Master Patent Status Chart as of September 30, 2019

PAVmed Code	Matter #	Country	Title	Application No. Application Date	Publication No. Publication Date	Patent No. Issue Date	Status
Port IO	010100/PRO	US	Long-Term Intraosseous Infusion Ports	62/079,266 11/13/2014			Expired
Port IO	010101/US	US	Intraosseous Infusion Ports	14/940,889 11/13/2015	2016-0136410 A1 5/19/2016	10,426,940 10/1/2019	Granted
Port IO	010102/PCT	PCT	Intraosseous Infusion Ports	PCT/US15/060669 11/13/2015	WO 2016/077748 5/19/2016		Nationalized, Expired
Port IO	010103/AU	Australia	Intraosseous Infusion Ports	2015346130 11/13/2015			Pending Application
Port IO	010104/CA	Canada	Intraosseous Infusion Ports	2967759 11/13/2015			Pending Application
Port IO	010105/CN	China	Intraosseous Infusion Ports	201580061766.3 11/13/2015	106999646A 8/1/2017		Pending Published
Port IO	010106/EP	Europe	Intraosseous Infusion Ports	15859903.5 11/13/2015	3218026 9/20/2017		Pending Published
Port IO	010107/JP	Japan	Intraosseous Infusion Ports	2017-544850 11/13/2015	2018-500145 1/11/2018		Pending Published
Port IO	010108/US/DIV	US	Intraosseous Infusion Ports	15/964,292 4/27/2018	2018-0256869 9/13/2018	10,434,296 10/8/2019	Granted
PortIO	010109/PRO	US	Infusion Ports and Methods of Use	62/820,742 3/19/2019			Pending Application
PortIO	010111/JP/DIV	JP	Infusion Ports and Methods of Use	2019-171926 9/20/2019			Pending Application
NextCath	010200/PRO	US	Self-Anchoring Catheters and Methods of Use	62/085,838 12/1/2014			Expired
NextCath	010201/US	US	Self-Anchoring Catheters and Methods of Use	14/956,141 12/1/2015	2016-0151608 A1 6/2/2016	10,252,034 4/9/2019	Granted
NextCath	010202/PCT	PCT	Self-Anchoring Catheters and Methods of Use	PCT/US15/063221 12/1/2015	WO 2016/089894 6/9/2016		Nationalized, Expired
NextCath	010204/AU	Australia	Self-Anchoring Catheters and Methods of Use	2015355062 12/1/2015			Pending Application
NextCath	010205/CA	Canada	Self-Anchoring Catheters and Methods of Use	2,969,448 12/1/2015			Pending Application
NextCath	010206/CN	China	Self-Anchoring Catheters and Methods of Use	201580065441.2 12/1/2015	107106813A 8/29/2017		Pending Published
NextCath	010207/EP	Europe	Self-Anchoring Catheters and Methods of Use	15865776.7 12/1/2015	3226955 10/11/2017		Pending Published
NextCath	010208/JP	Japan	Self-Anchoring Catheters and Methods of Use	2017-530180 12/1/2015			Pending Application
NextCath	010209/US/DIV1	US	Self-Anchoring Catheters and Methods of Use	16/251,372 1/18/2019	US-2019-0151618-A1 5/23/2019		Pending Published
NextCath	010210/US/DIV2	US	Self-Anchoring Catheters and Methods of Use	16/251,397 1/18/2019	US-2019-0151619-A1 5/23/2019		Pending Published
NextCath	010211/US/DIV3	US	Self-Anchoring Catheters and Methods of Use	16/251,411 1/18/2019	US-2019-0151620-A1 5/23/2019		Pending Published
NextCath	010212/JP/DIV	JP	Self-Anchoring Catheters and Methods of Use	2019-008109 12/1/2015	2019-088839 6/13/2019		Pending Published

PAVMED (155848) Master Patent Status Chart as of September 30, 2019

PAVmed Code	Matter #	Country	Title	Application No. Application Date	Publication No. Publication Date	Patent No. Issue Date	Status
CarpX	010300/PRO	US	Systems and Methods for Percutaneous Division of Fibrous Structures	62/086,950 12/3/2014			Expired
CarpX	010301/US	US	Systems and Methods for Percutaneous Division of Fibrous Structures	14/958,003 12/3/2015	2016-015780 A1 6/9/2016	10,335,189 7/2/2019	Granted
CarpX	010302/PCT	PCT	Systems and Methods for Percutaneous Division of Fibrous Structures	PCT/US15/063703 12/3/2015	WO 2016/090122 6/9/2016		Nationalized,Expired
CarpX	010304/AU	Australia	Systems and Methods for Percutaneous Division of Fibrous Structures	2015358424 12/3/2015			Pending Application
CarpX	010305/CA	Canada	Systems and Methods for Percutaneous Division of Fibrous Structures	2,969,579 12/3/2015			Pending Application
CarpX	010306/CN	China	Systems and Methods for Percutaneous Division of Fibrous Structures	201580072247.7 12/3/2015	107106200A 8/29/2017		Pending Published
CarpX	010307/EP	Europe	Systems and Methods for Percutaneous Division of Fibrous Structures	15865054.9 12/3/2015	3226783 10/11/2017		Pending Published
CarpX	010308/JP	Japan	Systems and Methods for Percutaneous Division of Fibrous Structures	2017-530119 12/3/2015	2018-501847 1/25/2018		Pending Published
CarpX	010309/US/DIV	US	Systems and Methods for Percutaneous Division of Fibrous Structures	15/964,531 4/27/2018	2018-0242995 8/30/2018		Pending Published
CarpX	010310/US/DIV	US	Systems and Methods for Percutaneous Division of Fibrous Structures	15/964,550 4/27/2018	2018-0271552 9/27/2018		Pending Published
CarpX	010320/PRO	US	CarpX with Nerve Sensing and Stimulator	TBD			To be filed
CarpX	010340/PRO	US	CarX with Control Unit Decoupled from Handle	TBD			To be filed

PAVMED (155848) Master Patent Status Chart as of September 30, 2019

PAVmed Code	Matter #	Country	Title	Application No. Application Date	Publication No. Publication Date	Patent No. Issue Date	Status
Caldus	010400/PRO	US	Continuous Flow Balloon Catheter Systems and Methods of Use	62/131,214 3/10/2015			Expired
Caldus	010401/PRO	US	Continuous Flow Thermal Ablation Balloon Catheter Systems and Methods of Use	62/131,217 3/10/2015			Expired
Caldus	010403/US	US	Continuous Flow Balloon Catheter Systems and Methods of Use	15/067,148 3/10/2016	2016-0262823 A1 9/15/2016	10,213,245 2/26/2019	Granted
Caldus	010404/PCT	PCT	Continuous Flow Balloon Catheter Systems and Methods of Use	PCT/US16/021804 3/10/2016	WO 2016/145214 9/15/2016		Expired
Caldus	010405/EP	EP	Continuous Flow Balloon Catheter Systems and Methods of Use	16762527.6 3/10/2016	3267955 1/17/2018		Pending Published
Caldus	010406/DIV1	US	Continuous Flow Balloon Catheter Systems and Methods of Use	15/923,140 3/16/2018	2018-0199983 7/19/2018		Pending Published
Caldus	010407/DIV2	US	Continuous Flow Balloon Catheter Systems and Methods of Use	15/923,224 3/16/2018	2018-0199984 7/19/2018		Pending Published
Caldus	010408/CON	US	Continuous Flow Balloon Catheter Systems and Methods of Use	16/254,717 1/23/2019	US-2019-0151007-A1 5/23/2019		Pending Published
NextFlo	010501/US (previously Pavilion Holdings 010301)	US	System and Methods for Infusion of Fluids Using Stored Potential Energy and A Variable Flow Resistor	13/041,296 3/4/2011	2011-0251579 10/13/2011	8,622,976 1/7/2014	Granted
NextFlo	010504/PCT/EP (previously Pavilion Holdings 010304)	EP	System and Methods for Infusion of Fluids Using Stored Potential Energy and A Variable Flow Resistor	11751472.9 3/4/2011	2542297 1/9/2013		Pending Published
NextFlo	010505/EP/DIV	EP	System and Methods for Infusion of Fluids Using Stored Potential Energy and A Variable Flow Resistor	19158839.1 3/4/2011	EP3511049 7/17/2019		Pending Published
NextFlo	010506/DIV (previously Pavilion Holdings 010306)	US	System and Methods for Infusion of Fluids Using Stored Potential Energy and A Variable Flow Resistor	14/094,046 12/2/2013	2014-0083529 A1 3/27/2017	9,155,834 10/13/2015	Granted
NextFlo	010508/PRO	US	Systems and Methods for a Variable Flow Resistor	62/832,005 4/10/2019			Pending Application

PAVMED (155848) Master Patent Status Chart as of September 30, 2019

PAVmed Code	Matter #	Country	Title	Application No. Application Date	Publication No. Publication Date	Patent No. Issue Date	Status
EsoCheck Gen 3	010801/PRO	PRO	A Catheter Device System and Method of Use	62/849,503 5/17/2019			Pending Application

**Case Western Reserve University
Patent Cases Status as of 10/18/19**

Reference Number	Application No. and Date	Country	Title	Inventors	Assignee/Applicant	Status
189573-010100/PRO	61/915029 12/12/2013	US	JAS BRUSH ESOPHAGEAL COLLECTION DEVICE	MARKOWITZ, SANFORD D; CHAK, Amitabh; WILLIS, Joseph E	CWRU	Expired
189573-010101/US	15/103,638 6/10/2016	US	DEVICE FOR COLLECTING A BIOLOGICAL SAMPLE	Sanford Markowitz, Amitabh Chak, Joseph Willis, Jeffrey Silver Taggart, Rebecca Blice, Dean Secret, Dennis Seidlak	CWRU	Abandoned (to be revived)
189573-010102/PCT	PCT/US14/70060 12/12/2014	PCT	DEVICE FOR COLLECTING A BIOLOGICAL SAMPLE	Sanford Markowitz, Amitabh Chak, Joseph Willis, Jeffrey Silver Taggart, Rebecca Blice, Dean Secret, Dennis Seidlak	CWRU	Expired
189573-010103/AU	2014361829 12/12/2014	AU	DEVICE FOR COLLECTING A BIOLOGICAL SAMPLE	Sanford Markowitz, Amitabh Chak, Joseph Willis, Jeffrey Silver Taggart, Rebecca Blice, Dean Secret, Dennis Seidlak	CWRU	Allowed
189573-010104/CA	2933550 12/12/2014	CA	DEVICE FOR COLLECTING A BIOLOGICAL SAMPLE	Sanford Markowitz, Amitabh Chak, Joseph Willis, Jeffrey Silver Taggart, Rebecca Blice, Dean Secret, Dennis Seidlak	CWRU	Published
189573-010105/EP	14870556 12/12/2014	EP	DEVICE FOR COLLECTING A BIOLOGICAL SAMPLE	Sanford Markowitz, Amitabh Chak, Joseph Willis, Jeffrey Silver Taggart, Rebecca Blice, Dean Secret, Dennis Seidlak	CWRU	Published
189573-010106/US/DIV	16/405634 5/7/2019	US	DEVICE FOR COLLECTING A BIOLOGICAL SAMPLE	Sanford Markowitz, Amitabh Chak, Joseph Willis, Jeffrey Silver Taggart, Rebecca Blice, Dean Secret, Dennis Seidlak	CWRU	Published
189573-010107/EP/DIV	To be filed					
189573-010108/AU/DIV	To be filed					
189573-010109/CA/DIV	To be filed					
010200/PRO	62/500933 5/3/2017	US	DEVICE FOR COLLECTING A BIOLOGICAL SAMPLE		CWRU	Expired
010201/PCT	PCT/US18/030907 5/3/2018	PCT	DEVICE FOR COLLECTING A BIOLOGICAL SAMPLE		CWRU	Published



Lucid Diagnostics, Inc. (182338) Master Trademark Status Chart

Matter #	Country	Title	Application No. Application Date	Registration No. Issue Date	Status	Inventor(s) /Applicant(s)
031101	US	ESOCHEK	88/096,114 8/23/2018		Abandoned	Lucid Diagnostics
031102	US	ESOCHECK CCD	88/274,813 1/24/19		Pending Published	Lucid Diagnostics
031103	US	ESOCHECK DX	88/274,816 1/24/19		Abandoned	Lucid Diagnostics
031104	Brazil	ESOCHECK CCD	916804283 2/22/19		Pending Allowed	Lucid Diagnostics
031104	Brazil	ESOCHECK CCD	916804372 2/22/19		Pending Allowed	Lucid Diagnostics
031105	Canada	ESOCHECK CCD	1947670 2/26/19		Pending Application	Lucid Diagnostics
031106	Europe	ESOCHECK CCD	018027287 2/26/19		Pending Published	Lucid Diagnostics
031107	Japan	ESOCHECK CCD	2019-28637 2/22/19		Pending Published	Lucid Diagnostics
031108	Brazil	ESOCHECK DX	916804437 2/22/19		Abandoned	Lucid Diagnostics
031108	Brazil	ESOCHECK DX	916804445 2/22/19		Abandoned	Lucid Diagnostics
031109	Canada	ESOCHECK DX	1947671 2/26/19		Abandoned	Lucid Diagnostics
031110	Europe	ESOCHECK DX	018027284 2/26/19		Abandoned	Lucid Diagnostics
031111	Japan	ESOCHECK DX	2019-28635 2/22/19		Abandoned	Lucid Diagnostics
031112	UK	ESOCHECK CCD	UK00003391816 4/12/19	UK00003391816 6/28/2019	Registered	Lucid Diagnostics
031300	US	ESOGUARD	88/347,269 3/19/19		Pending Application	Lucid Diagnostics
031301	AU	ESOGUARD	2005586 4/26/19		Pending Published	Lucid Diagnostics
031302	CA	ESOGUARD	1959088 4/24/19		Pending Application	Lucid Diagnostics
031303	EU	ESOGUARD	18055629 4/24/19	018055629 8/30/2019	Registered	Lucid Diagnostics
031304	JP	ESOGUARD	2019-61214 4/25/19		Pending Published	Lucid Diagnostics
031305	UK	ESOGUARD	UK00003394519 4/24/2019	UK00003394519 7/19/2019	Registered	Lucid Diagnostics

Lucid Diagnostics, Inc. (182338) Master Trademark Status Chart

Matter #	Country	Title	Application No. Application Date	Registration No. Issue Date	Status	Inventor(s) /Applicant(s)
031500	US	ESOCHECK	88/090,111 8/23/2018		Pending Allowed	Lucid Diagnostics
031501	AU	ESOCHECK	1998006 3/22/19		Pending Published	Lucid Diagnostics
031502	CA	ESOCHECK	1952856 3/21/19		Pending Application	Lucid Diagnostics
031503	EU	ESOCHECK	018051805 4/12/19	018051805 8/30/2019	Registered	Lucid Diagnostics
031504	JP	ESOCHECK	2019-41505 3/22/19		Pending Application	Lucid Diagnostics
031505	UK	ESOCHECK	UK00003391819 4/12/2019	UK00003391819 6/28/2019	Registered	Lucid Diagnostics
031600	US	ESOSURE	88/489,556 6/26/2019		Pending Application	Lucid Diagnostics
031601	US	ESOSURE	88/489,562 6/26/2019		Pending Application	Lucid Diagnostics
031900	US	COLLECT+PROTECT	88/489,566 6/26/2019		Pending Application	Lucid Diagnostics
031901	US	COLLECT+PROTECT	88/489,564 6/26/2019		Pending Application	Lucid Diagnostics

PAVMED (155848) Master Trademark Status Chart as of September 30, 2019

Matter #	Country	Title	Application No. Application Dat	Registration No. Issue Date	Status	Inventor(s) Applicant(s)
030100	US	PORTIO	86/464,855 11/25/2014		Abandoned	PAVmed, Inc.
030200/1	US	PAXMED	88/202,914 11/21/2018		Pending Application	PAVmed, Inc.
030200/US	US	PAXMED	86603808 4/20/2015		Lapsed	PAVmed, Inc.
030300/1	US	PAVILION	88/202,918 11/21/2018		Pending Published	PAVmed, Inc.
030300/US	US	PAVILION	86603802 4/20/2015		Lapsed	PAVmed, Inc.
030400/1	US	PAVILION MEDICAL	88/202,925 11/21/2018		Pending Published	PAVmed, Inc.
030400/US	US	PAVILION MEDICAL	88603804 4/20/2015		Lapsed	PAVmed, Inc.
030500/1	US	PAVmed (caps and small letters)	88/202,913 11/21/2018		Pending Application	PAVmed, Inc.
030500/US	US	PAVmed (caps and small letters)	86603807 4/20/2015		Lapsed	PAVmed, Inc.
030700/1	US	PAVMED (logo) 	88/202,911 11/21/2018		Pending Published	PAVmed, Inc.
030700/US	US	PAVMED (logo) 	86603808 4/20/2015		Lapsed	PAVmed, Inc.
030800/1	US	INNOVATING AT THE SPEED OF LIFE	88/202,927 11/21/2018		Pending Published	PAVmed, Inc.
030800/US	US	INNOVATING AT THE SPEED OF LIFE	86/641,166 5/26/2015		Lapsed	PAVmed, Inc.
030900	US	CARPX	87/828,085 3/9/2018		Pending Allowed	PAVmed, Inc.
030901	EU	CARPX	17885979 4/10/2018	017885978 8/20/2018	Registered	PAVmed, Inc.
030902	UK	CARPX	UK00003302860 4/10/2018	UK00003302860 7/13/2018	Registered	PAVmed, Inc.
030903	Brazil	CARPX	915801930 9/4/2018	915801930 7/30/2019	Registered	PAVmed, Inc.
030904	Japan	CARPX	2018-95208 7/25/2018	6104949 12/7/2018	Registered	PAVmed, Inc.
030905	Canada	CARPX	1913149 8/2/2018		Pending Application	PAVmed, Inc.
030906	Australia	CARPX	1998007 3/22/2019		Pending Published	PAVmed, Inc.
031000	US	CARPEX	87/828,080 2/9/2018		Abandoned	PAVmed, Inc.
34736563 031100	US	DEFY GRAVITY	88602470 9/3/2019		Pending Application	PAVmed, Inc.

TRADEMARK

SUMMARY TUFTS SILK PATENT PORTFOLIO as of 10-11-2019

Country	Status	Client Ref.	Filing Date	Title	Application No/ Patent Number or publication no	Issue Date/ Expiration Date	
CA	Granted	T001219 CA/MIT97 99	6/24/ 03	SILK BIOMATERIALS AND METHODS OF USE THEREOF	2525994/ 2525994	10/6/12 6/24/23	
EP validate in FR, DE, UK HK	Granted	T001219 DE/MIT97 99	6/24/ 03	SILK BIOMATERIALS AND METHODS OF USE THEREOF	03761306.4 EP1558444	9/21/16 6/24/23	
JP	Granted	T001219	6/24/ 03	SILK BIOMATERIALS AND METHODS OF USE THEREOF	2004-530973 JP4638735	12/3/10 6/24/23	
US	Granted	T001219	12/23 /04	SILK BIOMATERIALS AND METHODS OF USE THEREOF	11/020,650 7,674,882	3/9/10 2/9/26	
JP	Granted	T001219J PDIV2	6/24/ 03	SILK BIOMATERIALS AND METHODS OF USE THEREOF	JP 2014138877 JP5855151	12/18/15 6/24/23	
EP	Pending	T001219 EP DIV	6/24/ 03	SILK BIOMATERIALS AND METHODS OF USE THEREOF	17205284.7 EP3351376	TBD	

US	Granted	T001219	1/15/ 10	SILK BIOMATERIALS AND METHODS OF USE THEREOF	12/688,014 8,071,722	12/6/11 6/24/23	
CA	Pending	T001274 CA	6/13 /05	SILK BASED DRUG DELIVERY SYSTEM	2608862	6/13/05 6/13/25	
US	Allowed	T001274	12/3 /13	SILK BASED DRUG DELIVERY SYSTEM	14/095366	TBD	
AU	Pending	T001593 AUDIV3	3/4/ 10	SILK BASED DRUG DELIVERY SYSTEM	201826753 9	TBD	
EP	Pending	T001593	3/4/ 10	SILK BASED DRUG DELIVERY SYSTEM	10783739.5	TBD	
JP	Granted	T001593 JP	3/4/ 10	SILK FIBROIN SYSTEMS FOR ANTIBIOTIC DELIVERY	2015- 222744 JP6301896	3/28/18 3/4/30	
JP	Pending	T001593 JPDIV2	3/4/ 10	SILK FIBROIN SYSTEMS FOR ANTIBIOTIC DELIVERY	2017- 216415	TBD	
US	Pending	T001593 CON	7/12 /18	SILK FIBROIN SYSTEMS FOR ANTIBIOTIC DELIVERY	16/033,650	TBD	

US/EPO /JP/CN	Pending	T002017	7/28 /16	Water-Based Silk Monoliths	Based on PCT/US2016 /044411	TBD	
------------------	---------	---------	-------------	-------------------------------	-----------------------------------	-----	--

Schedule C

Copyrights

None.